SERD Therapeutics Market Vendor and Technology Assessment Report 2024-2031

SERD Therapeutics Market worth $ 6.38 Billion by 2031 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "SERD Therapeutics Market by Products (Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products), By Indication (ER-positive, HER2-negative, ESR1-mutated advanced or Metastatic Breast Cancer) - Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030"

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1246

InsightAce Analytics' most Recent research indicates that the global market for SERD therapies was valued at US$ 1.50 billion in 2022 and is projected to grow to US$ 6.38 billion in 2031, with a promising compound annual growth rate (CAGR) of 17.5% from 2023 to 2031.

The high incidence of breast cancer, the growing need for SERD therapies, and the growing number of clinical studies are the main factors propelling the SERD therapeutics market. Additionally, population increase, the rapid adoption of cutting-edge medical technology, and an increasing number of health-conscious individuals will all contribute to the SERD therapies market's expansion. However, this market's growth is being constrained by the high cost of the devices, the difficulty of the operations, and the opposition to endocrine therapy. Additionally, because of the lockdown conditions, the COVID-19 pandemic has had both beneficial and bad effects on the market for SERD medicines.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Major key Players in the SERD therapeutics market are
• Amneal Pharmaceuticals Inc
• AstraZeneca, Plc.
• Reddy's Laboratories
• Eli Lilly and Company
• G1 Therapeutics, Inc.
• Glenmark Pharmaceuticals
• HBT Labs, Inc
• Hoffmann-La Roche AG
• InventisBio
• Novartis AG
• Radius Health
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Zenopharm LLC.
• Zentalis Pharmaceuticals
• Genentech
• Olema Pharmaceuticals
• Aragon Pharmaceuticals
• Sun Pharma Advanced Research Company
• Shandong Luoxin Pharmaceutical
• Zeno Alpha
• Atossa Therapeutics
• Evestra

Recent Key Developments:
• In June 2021, Eli Lilly and Company presented new results for the exploratory use of Verzenio® (abemaciclib) in high-risk early breast cancer, as well as for its oral selective oestrogen receptor degrader (SERD) LY3484356 (ASCO). Lilly is releasing an exploratory analysis from the positive Phase 3 monarch study testing Verzenio, a CDK4/6 inhibitor, in a subset of patients with HR+, HER2-, high-risk early breast cancer (EBC) who had had neoadjuvant chemotherapy.
• In Sept 2020, InventisBio recently announced the conclusion of a $147 million series D fundraising, which included several of the world's leading biopharmaceutical and healthcare venture capital firms. InventisBio currently has three medicinal compounds in various stages of clinical development, and one new product has recently begun a worldwide phase I clinical trial. D-0502 showed remarkable anti-tumour effectiveness in phase 1 research, with superior absorption and an acceptable safety profile when compared to other oral SERDs in clinical development throughout the world.
• In Sept 2019, Preliminary data from a Phase 1/2a dose-escalation trial of G1T48, an oral selective oestrogen receptor degrader (SERD), in patients with oestrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer were released by G1 Therapeutics, Inc. G1T48 was well tolerated in the study and showed anti-tumour effectiveness in patients who had been substantially pre-treated. The results of this trial support the future development of G1T48 in both first line and adjuvant settings, and a first-line Phase 3 pivotal trial is expected to begin in 2020.

One class of medication that downregulates the estrogen receptor is called a selective estrogen receptor degrader (SERD). For HR-positive breast cancer, SERD and complete receptor antagonists are crucial therapeutic alternatives. Examples of endocrine medications include aromatase inhibitors, which stop the production of estrogen but result in acquired resistance, and tamoxifen, a specific estrogen receptor modulator (SERM) with receptor agonist and antagonist effect. The sole SERD that is currently licensed, Fluvastatin, exhibits minimal drug-like properties. One of the main goals for improving illness treatment has been the development of oral SERDs with optimal target occupancy and potency as well as improved clinical performance. The market for SERD medicines is expected to rise during the forecast period due to rising investments made by major players in the creation of potential treatments for breast cancer.

Due to growing government investments in the research and development of treatments for various cancer diseases, increased awareness of SERD therapies, and the rising incidence of breast cancer, the North American region accounts for the majority of this market's revenue at the regional level. However, because of the growing prevalence of chronic diseases, strict regulations, and developments in the biopharmaceutical industry, the Europe region will also lead the market throughout the forecast period. The expanding SERD therapeutic industries and the Quick adoption of new technologies are expected to drive the Asia-Pacific market's future growth.

Leading manufacturers in this field are focusing on novel SERD therapy innovations, making new partnerships, collaborations and agreements, growing awareness about SERD therapies, and increasing research investments for developing advanced technologies. These strategies will propel their growth opportunities in the market. In 2020, QLHC announced an evaluation of Sanofi's SAR439859, an oral estrogen receptor degrader (SERD), in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. AstraZeneca moved its next-generation oral SERD AZD9833 into phase 1 in 2018. While work on AZD9496 stalled after a few early clinical trials, AstraZeneca has quickly expanded and advanced the development of AZD9833. Late last month, AstraZeneca began enrolling patients in the phase 3 clinical trial of AZD9833.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/1246

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Products
• Faslodex
• Elacestrant
• Camizestrant (AZD9833)
• Giredestrant (GDC-9545)
• Imlunestrant (LY3484356)
• Other Pipeline Products
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Route Of Administration
• Intramuscular
• Oral
• Infusion
• Subcutaneous
• Parenteral
• Other
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Indication
• ER-positive
• HER2-negative
• ESR1-mutated advanced or metastatic breast cancer
• Other

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• U.S.
• Canada
Europe SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ www.insightaceanalytic.com/buy-report/1246

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.